These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31135100)

  • 1. Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
    Buscemi S; Randazzo C; Buscemi C
    J Diabetes Investig; 2019 Nov; 10(6):1595-1596. PubMed ID: 31135100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
    Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
    Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
    Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
    Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
    Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
    J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
    Evans M; Moes RGJ; Pedersen KS; Gundgaard J; Pieber TR
    Adv Ther; 2020 May; 37(5):2413-2426. PubMed ID: 32306247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes.
    Chatterjee S; Khunti K; Davies MJ
    Drugs; 2019 Feb; 79(2):173-186. PubMed ID: 30623349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.
    Martin ; Zhou Y; Takagi T; Tian YS
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2091-2101. PubMed ID: 34319421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec.
    Takahashi N; Tsujimoto T; Inoue K; Kishimoto M; Kajio H
    J Diabetes Investig; 2016 Sep; 7(5):805-6. PubMed ID: 27586093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of degludec insulin: a meta-analysis of randomised trials.
    Monami M; Mannucci E
    Curr Med Res Opin; 2013 Apr; 29(4):339-42. PubMed ID: 23368895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
    Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
    Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
    Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
    Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of basal insulins: A review.
    Vargas-Uricoechea H; Aschner P
    Diabetes Metab Syndr; 2021; 15(6):102318. PubMed ID: 34695771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
    Yamabe M
    J Diabetes Investig; 2019 Nov; 10(6):1597-1598. PubMed ID: 31608592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Madenidou AV; Paschos P; Karagiannis T; Katsoula A; Athanasiadou E; Kitsios K; Bekiari E; Matthews DR; Tsapas A
    Ann Intern Med; 2018 Aug; 169(3):165-174. PubMed ID: 29987326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
    Khunti K; Cos X; Rutten G
    Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.
    Yamamoto C; Miyoshi H; Fujiwara Y; Kameda R; Ichiyama M; Nomoto H; Kameda H; Nakamura A; Atsumi T
    Endocr J; 2016; 63(1):53-60. PubMed ID: 26522272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
    Russel-Szymczyk M; Valov V; Savova A; Manova M
    BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.